[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation]

Area of Science:

• Oncology
• Pharmacology

Background:

• Endothelial growth factor receptor (EGFR) mutations are key in non-small cell lung carcinoma (NSCLC) personalized medicine.
• First-generation tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib showed improved progression-free survival (PFS) versus chemotherapy in EGFR-mutated NSCLC.
• Afatinib, a second-generation irreversible pan-ErbB inhibitor, demonstrated overall survival (OS) benefit in first-line treatment for EGFR mutation-positive NSCLC.

Purpose of the Study:

• To evaluate the efficacy of afatinib compared to gefitinib as a first-line treatment for NSCLC patients with specific EGFR mutations.
• To analyze the impact of different EGFR mutation types (Exon 19 deletion and L858R) on treatment outcomes.

Main Methods:

• Analysis of data from the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 clinical trials.
• Comparison of progression-free survival (PFS) and overall survival (OS) between treatment arms.
• Subgroup analysis based on EGFR mutation status (Exon 19 deletion vs. L858R).

Main Results:

• Afatinib showed a statistically significant increase in PFS compared to gefitinib in the LUX-Lung 7 trial (HR: 0.73).
• Afatinib demonstrated a statistically significant increase in OS for patients with the Del19 mutation in LUX-Lung 3 and 6 trials.
• The PFS benefit of afatinib over gefitinib in LUX-Lung 7 was observed for both Del19 and L858R mutations.

Conclusions:

• Afatinib represents a significant advancement in first-line treatment for EGFR mutation-positive NSCLC.
• Treatment outcomes may vary depending on the specific EGFR mutation type.
• Afatinib provides a survival benefit in NSCLC patients with activating EGFR mutations.